One possibility may be through the use of increased DNA sensing by TLR9 on CD8+ T cells in mice treated with DNAse I. It has been demonstrated that the TLR9 agonist effectively increases tumor infiltration by CD8+T cells [58]. The gene discussed is CD8A; the disease is neoplasm.